ISOTRETINOIN AND MOOD DISORDERS IN PATIENTS WITH ACNE VULGARIS - LITERATURE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5962Keywords:
Acne Vulgaris, Isotretinoin, Depression, Quality of Life, Depressive Symptoms, Mood DisordersAbstract
Introduction and Aim: Acne vulgaris is among the most prevalent dermatological conditions affecting adolescents and young adults. Visible acne lesions may considerably reduce quality of life, negatively influence self-esteem, and impair social functioning. Oral isotretinoin is widely considered the treatment of choice for severe and therapy-resistant acne. Nevertheless, concerns have long been raised regarding its potential association with psychiatric symptoms, particularly mood disturbances, depression, and suicidal behaviour. The purpose of this review is to summarise current clinical evidence concerning the relationship between isotretinoin therapy and mood disorders in patients with acne vulgaris, with particular attention to factors that may explain the observed clinical outcomes.
Material and Methods: A narrative literature review was performed using advanced searches in the PubMed database. The analysis included English-language publications from the last five years, such as clinical and observational studies, systematic reviews, and meta-analyses focusing on depressive symptoms, psychiatric adverse events, and quality-of-life changes among patients receiving isotretinoin for acne vulgaris.
Conclusions: The currently available evidence does not conclusively demonstrate a clinically meaningful increase in depression risk in the general population of patients treated with isotretinoin. However, in some individuals, specific vulnerability factors may increase susceptibility to mood disturbances, supporting the need for careful psychological monitoring during therapy. In many patients, improvement in acne severity is accompanied by better well-being and enhanced quality of life. Further research is required to clarify the neurobiological mechanisms underlying isotretinoin activity and to identify patients at greatest risk of psychiatric complications. These findings emphasize the importance of individualized risk–benefit assessment and close cooperation between dermatologists, general practitioners, and mental health specialists.
References
Heng, A. H. S., & Chew, F. T. (2020). Systematic review of the epidemiology of acne vulgaris. Scientific Reports, 10(1), 5754. https://doi.org/10.1038/s41598-020-62715-3
Melnik, B. C. (2023). Acne transcriptomics: Fundamentals of acne pathogenesis and isotretinoin treatment. Cells, 12(22), 2600. https://doi.org/10.3390/cells12222600
Kutlu, Ö., Karadağ, A. S., & Wollina, U. (2023). Adult acne versus adolescent acne: A narrative review with a focus on epidemiology to treatment. Anais Brasileiros de Dermatologia, 98(1), 75–83. https://doi.org/10.1016/j.abd.2022.01.006
Singer, S., Tkachenko, E., Sharma, P., Barbieri, J. S., & Mostaghimi, A. (2019). Psychiatric adverse events in patients taking isotretinoin as reported in a Food and Drug Administration database from 1997 to 2017. JAMA Dermatology, 155(10), 1162–1166. https://doi.org/10.1001/jamadermatol.2019.1416
Li, C., Chen, J., Wang, W., Ai, M., Zhang, Q., & Kuang, L. (2019). Use of isotretinoin and risk of depression in patients with acne: A systematic review and meta-analysis. BMJ Open, 9(1), e021549. https://doi.org/10.1136/bmjopen-2018-021549
Magin, P., Pond, D., & Smith, W. (2005). Isotretinoin, depression and suicide: A review of the evidence. The British Journal of General Practice: The Journal of the Royal College of General Practitioners, 55(511), 134–138.
Santer, M., Burden-Teh, E., & Ravenscroft, J. (2023). Managing acne vulgaris: An update. Drug and Therapeutics Bulletin, 62(1), 6–10. https://doi.org/10.1136/dtb.2023.000051
Gradwohl, K., Verghese, M., & Rosenblatt, A. E. (2023). Mood changes and clinical decision making in adolescent patients on isotretinoin therapy for acne vulgaris. Pediatric Dermatology, 40(3), 494–496. https://doi.org/10.1111/pde.15324
Rajput, I., & Anjankar, V. P. (2024). Side effects of treating acne vulgaris with isotretinoin: A systematic review. Cureus, 16(3), e55946. https://doi.org/10.7759/cureus.55946
Woodie, B. R., Holt, I. N., Freking, J. A., Harrison, H. C. W., Rivin, G. M., & Fleischer, A. B., Jr. (2025). Severity of acne vulgaris predicts maladaptive psychosocial perceptions and neuropsychiatric disorders: A case-control study. Archives of Dermatological Research, 317(1), 597. https://doi.org/10.1007/s00403-025-04123-z
Hughes, O., & Bewley, A. (2023). Is it really ever ‘just acne’? Considering the psychodermatology of acne. The British Journal of Dermatology, 189(Suppl. 1), i11–i16. https://doi.org/10.1093/bjd/ljad251
Stamu-O’Brien, C., Jafferany, M., Carniciu, S., & Abdelmaksoud, A. (2021). Psychodermatology of acne: Psychological aspects and effects of acne vulgaris. Journal of Cosmetic Dermatology, 20(4), 1080–1083. https://doi.org/10.1111/jocd.13765
Paljarvi, T., McPherson, T., Luciano, S., Herttua, K., & Fazel, S. (2022). Isotretinoin and adverse neuropsychiatric outcomes: Retrospective cohort study using routine data. The British Journal of Dermatology, 187(1), 64–72. https://doi.org/10.1111/bjd.21049
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dominika Weronika Brożyna, Jarosław Dudek, Wojciech Kukiełka, Damian Grębosz, Wiktoria Komornik, Michał Łebek, Mateusz Wnęk, Michalina Pastuszka, Bartłomiej Andrzej Sałapski, Wiktor Zdeb
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
